Faculty Opinions recommendation of Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Lymphocytic Leukaemia ◽

Small Lymphocytic Lymphoma ◽

Phase 3 ◽

Double Blind ◽

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)00465-9 ◽

2016 ◽

Vol 17 (2) ◽

pp. 200-211 ◽

Cited By ~ 247

Author(s):

Asher Chanan-Khan ◽

Paula Cramer ◽

Fatih Demirkan ◽

Graeme Fraser ◽

Rodrigo Santucci Silva ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Small Lymphocytic Lymphoma ◽

Phase 3 ◽

Double Blind ◽

Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30168-0 ◽

2017 ◽

Vol 4 (11) ◽

pp. e534-e543 ◽

Cited By ~ 20

Author(s):

Asher A Chanan-Khan ◽

Andrey Zaritskey ◽

Miklos Egyed ◽

Samuel Vokurka ◽

Sergey Semochkin ◽

...

Keyword(s):

Maintenance Therapy ◽

Lymphocytic Leukaemia ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727373020.793562618 ◽

2019 ◽

Author(s):

Corrado Girmenia

Keyword(s):

Lymphocytic Leukaemia ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727373020.793538186 ◽

2017 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Lymphocytic Leukaemia ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30671-4 ◽

2017 ◽

Vol 18 (3) ◽

pp. 297-311 ◽

Cited By ~ 128

Author(s):

Andrew D Zelenetz ◽

Jacqueline C Barrientos ◽

Jennifer R Brown ◽

Bertrand Coiffier ◽

Julio Delgado ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Controlled Trial ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(11)70242-x ◽

2011 ◽

Vol 12 (13) ◽

pp. 1204-1213 ◽

Cited By ~ 64

Author(s):

Thomas Elter ◽

Liana Gercheva-Kyuchukova ◽

Halyna Pylylpenko ◽

Tadesuz Robak ◽

Branimir Jaksic ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Phase 3 ◽

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30019-4 ◽

2017 ◽

Vol 4 (3) ◽

pp. e114-e126 ◽

Cited By ~ 107

Author(s):

Jeffrey A Jones ◽

Tadeusz Robak ◽

Jennifer R Brown ◽

Farrukh T Awan ◽

Xavier Badoux ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727253578.793538185 ◽

2017 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Lymphocytic Leukaemia ◽

Controlled Trial ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Faculty Opinions recommendation of Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727253578.793562619 ◽

2019 ◽

Author(s):

Corrado Girmenia

Keyword(s):

Lymphocytic Leukaemia ◽

Controlled Trial ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study

The Lancet Haematology ◽

10.1016/s2352-3026(17)30171-0 ◽

2017 ◽

Vol 4 (10) ◽

pp. e475-e486 ◽

Cited By ~ 26

Author(s):

Anna Maria Fink ◽

Jasmin Bahlo ◽

Sandra Robrecht ◽

Othman Al-Sawaf ◽

Ali Aldaoud ◽

...

Keyword(s):

High Risk ◽

Lymphocytic Leukaemia ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy